Literature DB >> 10597265

BRCA1 signals ARF-dependent stabilization and coactivation of p53.

K Somasundaram1, T K MacLachlan, T F Burns, M Sgagias, K H Cowan, B L Weber, W S el-Deiry.   

Abstract

The hereditary breast and ovarian tumor suppressor BRCA1 can activate p53-dependent gene expression. We show here that BRCA1 increases p53 protein levels through a post-transcriptional mechanism. BRCA1-stabilized p53 has increased sequence-specific DNA-binding and transcriptional activity. BRCA1 does not stabilize p53 in p14ARF-deficient cells. A deletion mutant of BRCA1 which inhibits p53-dependent transcription confers resistance to topoisomerase II-targeted chemotherapy. Our results suggest that BRCA1 may trigger the p53 pathway through two potentially separate mechanisms: accumulation of p53 through a direct or indirect induction of p14ARF as well as direct transcriptional coactivation of p53. BRCA1 may also enhance chemosensitivity and repair of DNA damage through binding to and coactivation of p53.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10597265     DOI: 10.1038/sj.onc.1203284

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  ZBP-89 promotes growth arrest through stabilization of p53.

Authors:  L Bai; J L Merchant
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

Review 2.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

3.  BRCA1 at a branch point.

Authors:  J D Parvin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

4.  BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets.

Authors:  Timothy K MacLachlan; Rishu Takimoto; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

5.  Direct DNA binding by Brca1.

Authors:  T T Paull; D Cortez; B Bowers; S J Elledge; M Gellert
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

6.  Differential effects of HTLV-1 Tax oncoprotein on the different estrogen-induced-ER α-mediated transcriptional activities.

Authors:  Ammar Abou-Kandil; Nora Eisa; Azhar Jabareen; Mahmoud Huleihel
Journal:  Cell Cycle       Date:  2016-07-15       Impact factor: 4.534

7.  Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin.

Authors:  Huchun Li; Masayuki Sekine; Nadine Tung; Hava Karsenty Avraham
Journal:  Mol Cancer Res       Date:  2010-03-09       Impact factor: 5.852

8.  Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor.

Authors:  Sonia Rocha; Michelle D Garrett; Kirsteen J Campbell; Katie Schumm; Neil D Perkins
Journal:  EMBO J       Date:  2005-03-10       Impact factor: 11.598

9.  Identification of DBC1 as a transcriptional repressor for BRCA1.

Authors:  H Hiraike; O Wada-Hiraike; S Nakagawa; S Koyama; Y Miyamoto; K Sone; M Tanikawa; T Tsuruga; K Nagasaka; Y Matsumoto; K Oda; K Shoji; H Fukuhara; S Saji; K Nakagawa; S Kato; T Yano; Y Taketani
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

10.  BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells.

Authors:  Akiko Horiuchi; Cuiju Wang; Norihiko Kikuchi; Ryosuke Osada; Toshio Nikaido; Ikuo Konishi
Journal:  Biomark Insights       Date:  2007-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.